Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | LDHB | P07195 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL729425 | 0.82 | ALDH1A1 (0.36) | ALDH1A1TSHRFGFR4 | |
| SCHEMBL8570758 | 0.80 | ALDH1A1 (0.35) | ALDH1A1TSHRFGFR4LDHALDHB | |
| SCHEMBL8760513 | 0.80 | ALDH1A1 (0.35) | ALDH1A1TSHRFGFR4LDHALDHB | |
| SCHEMBL8105045 | 0.76 | ALDH1A1 (0.32) | ALDH1A1TSHRFGFR4LMNA | |
| SCHEMBL729717 | 0.74 | LMNA (0.33) | ALDH1A1TSHRLMNA | |
| SCHEMBL211112 | 0.72 | LMNA (0.32) | LMNA | |
| Urea SCHEMBL11879610 | 0.70 | ALDH1A1 (0.45) | ALDH1A1TSHRFGFR4LDHALDHB | |
| SCHEMBL362181 | 0.70 | ALDH1A1 (0.35) | ALDH1A1LMNA | |
| SCHEMBL8575133 | 0.70 | ALDH1A1 (0.35) | ALDH1A1TSHRFGFR4 | |
| SCHEMBL8570759 | 0.70 | ALDH1A1 (0.35) | ALDH1A1TSHRFGFR4LDHALDHB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4751557-B2 | — | — | 2011-08-17 | — | — | JP | claimed |
| EP-1278717-B1 | ONE-POT SYNTHESIS OF ALKYL 3-CYCLOPROPYLAMINO-2- 2,4-DIBROMO-3-(DIFLUOROMETHOXY)BENZOYL|-2-PROPENOATE AS A USEFUL INTERMEDIATE FOR ANTIBACTERIAL QUINOLONE MEDICAMENTS | RANBAXY LAB LTD (IN) | 2007-06-06 | — | — | EP | claimed |
| EP-1278717-A4 | ONE-POT SYNTHESIS OF ALKYL 3-CYCLOPROPYLAMINO-2- 2,4-DIBROMO-3-(DIFLUOROMETHOXY)BENZOYL]-2-PROPENOATE AS A USEFUL INTERMEDIATE FOR ANTIBACTERIAL QUINOLONE MEDICAMENTS | RANBAXY LAB LTD (IN) | 2005-06-08 | — | — | EP | claimed |
| US-20040267019-A1 | ONE-POT SYNTHESIS OF ALKYL 3-CYCLOPROPYLAMINO -2-[2,4-DIBROMO-3-(DIFLUROMETHOXY) BENZOYL]-2-PROPENOATE AS A USEFUL INTERMEDIATE FOR ANTIBACTERIAL QUINOLONE MEDICAMENTS | TOYAMA CHEMICAL COMPANY, LIMITED (JP) | 2004-12-30 | — | — | US | claimed |
| US-6835848-B1 | Reacting 2,4-dibromo-3-(difluoromethoxy)benzoic acid with a halogenating agent to get a corresponding acid chloride, then reacting with a 3-(dialkylamino)acrylic acid alkyl ester and then cyclopropylamine | RANBAXY LABORATORIES LIMITED (IN) | 2004-12-28 | — | — | US | claimed |
| EP-1278717-A1 | ONE-POT SYNTHESIS OF ALKYL 3-CYCLOPROPYLAMINO-2- 2,4-DIBROMO-3-(DIFLUOROMETHOXY)BENZOYL]-2-PROPENOATE AS A USEFUL INTERMEDIATE FOR ANTIBACTERIAL QUINOLONE MEDICAMENTS | Ranbaxy Laboratories Limited (IN) | 2003-01-29 | — | — | EP | claimed |
| WO-2001066512-A1 | ONE-POT SYNTHESIS OF ALKYL 3-CYCLOPROPYLAMINO-2-[2,4-DIBROMO-3-(DIFLUOROMETHOXY)BENZOYL]-2-PROPENOATE AS A USEFUL INTERMEDIATE FOR ANTIBACTERIAL QUINOLONE MEDICAMENTS | RANBAXY LABORATORIES LIMITED (IN) | 2001-09-13 | — | — | WO | claimed |
| US-8629288-B2 | Method for the regioselective synthesis of 1-alky1-3-haloalkyl-pyrazole-4-carboxylic acid derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-8350053-B2 | Process for the regioselective preparation of 1-alkyl-3-haloalkylpyrazole-4-carboxylic acid derivatives | BAYER CROPSCIENCE AG (DE) | 2013-01-08 | — | — | US | disclosed |
| US-8136676-B2 | a membrane or fibers composed of or coated with methoxyethyl methacrylate/2-/-di(ethylene glycol)ethyl ether methacrylate-2-(diethylamino)ethyl methacrylate terpolymer for the selective removal, reduction or separation of white blood cells and/or platelets from blood by passing blood through the medium | UNIVERSITY OF SOUTHAMPTON (GB) | 2012-03-20 | — | — | US | disclosed |
| US-20110028735-A1 | Process for the Regioselective Preparation of 1-Alkyl-3-haloalkylpyrazole-4-carboxylic Acid Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-02-03 | — | — | US | disclosed |
| US-20110009642-A1 | Method for the Regioselective Synthesis of 1-Alkyl-3-haloalkyl-pyrazole-4-carboxylic Acid Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20080190843-A1 | Polymers Useful as Medical Materials | UNIVERSITY OF SOUTHAMPTON (GB) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028735-A1 | Process for the Regioselective Preparation of 1-Alkyl-3-haloalkylpyrazole-4-carboxylic Acid Derivatives | HCAR3, AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ALDH1A1 68/4885TSHR 3439/4885FGFR4 875/4885 |
| US-20110009642-A1 | Method for the Regioselective Synthesis of 1-Alkyl-3-haloalkyl-pyrazole-4-carboxylic Acid Derivatives | ATL3, HCAR3, AADAC | ALDH1A1 104/4885TSHR 2648/4885FGFR4 1464/4885 |
| US-20040267019-A1 | ONE-POT SYNTHESIS OF ALKYL 3-CYCLOPROPYLAMINO -2-[2,4-DIBROMO-3-(DIFLUROMETHOXY) BENZOYL]-2-PROPENOATE AS A USEFUL INTERMEDIATE FOR ANTIBACTERIAL QUINOLONE MEDICAMENTS | TET2, TET3, TET1 | ALDH1A1 1331/4885TSHR 3668/4885FGFR4 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.